CABA
Price
$2.34
Change
-$0.09 (-3.70%)
Updated
Dec 2, 04:59 PM (EDT)
Capitalization
233.92M
100 days until earnings call
Intraday BUY SELL Signals
CRSP
Price
$51.58
Change
-$0.59 (-1.13%)
Updated
Dec 2, 04:59 PM (EDT)
Capitalization
4.97B
77 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CABA vs CRSP

Header iconCABA vs CRSP Comparison
Open Charts CABA vs CRSPBanner chart's image
Cabaletta Bio
Price$2.34
Change-$0.09 (-3.70%)
Volume$37.92K
Capitalization233.92M
CRISPR Therapeutics AG
Price$51.58
Change-$0.59 (-1.13%)
Volume$19.83K
Capitalization4.97B
CABA vs CRSP Comparison Chart in %
CABA
Daily Signal:
Gain/Loss:
CRSP
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CABA vs. CRSP commentary
Dec 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CABA is a StrongBuy and CRSP is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 03, 2025
Stock price -- (CABA: $2.43 vs. CRSP: $52.17)
Brand notoriety: CABA and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CABA: 32% vs. CRSP: 87%
Market capitalization -- CABA: $233.92M vs. CRSP: $4.97B
CABA [@Biotechnology] is valued at $233.92M. CRSP’s [@Biotechnology] market capitalization is $4.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CABA’s FA Score shows that 1 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • CABA’s FA Score: 1 green, 4 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, CABA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CABA’s TA Score shows that 4 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • CABA’s TA Score: 4 bullish, 6 bearish.
  • CRSP’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both CABA and CRSP are a bad buy in the short-term.

Price Growth

CABA (@Biotechnology) experienced а +5.65% price change this week, while CRSP (@Biotechnology) price change was +1.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.65%. For the same industry, the average monthly price growth was -4.59%, and the average quarterly price growth was +53.79%.

Reported Earning Dates

CABA is expected to report earnings on Mar 12, 2026.

CRSP is expected to report earnings on Feb 17, 2026.

Industries' Descriptions

@Biotechnology (-1.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.97B) has a higher market cap than CABA($234M). CRSP YTD gains are higher at: 32.546 vs. CABA (7.048). CABA has higher annual earnings (EBITDA): -140.83M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. CABA (195M). CABA has less debt than CRSP: CABA (24.9M) vs CRSP (215M). CRSP has higher revenues than CABA: CRSP (35M) vs CABA (0).
CABACRSPCABA / CRSP
Capitalization234M4.97B5%
EBITDA-140.83M-533.5M26%
Gain YTD7.04832.54622%
P/E RatioN/AN/A-
Revenue035M-
Total Cash195M1.72B11%
Total Debt24.9M215M12%
FUNDAMENTALS RATINGS
CABA vs CRSP: Fundamental Ratings
CABA
CRSP
OUTLOOK RATING
1..100
7310
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9692
PRICE GROWTH RATING
1..100
3952
P/E GROWTH RATING
1..100
10070
SEASONALITY SCORE
1..100
3n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CABA's Valuation (16) in the null industry is somewhat better than the same rating for CRSP (72) in the Biotechnology industry. This means that CABA’s stock grew somewhat faster than CRSP’s over the last 12 months.

CABA's Profit vs Risk Rating (100) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that CABA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (92) in the Biotechnology industry is in the same range as CABA (96) in the null industry. This means that CRSP’s stock grew similarly to CABA’s over the last 12 months.

CABA's Price Growth Rating (39) in the null industry is in the same range as CRSP (52) in the Biotechnology industry. This means that CABA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (70) in the Biotechnology industry is in the same range as CABA (100) in the null industry. This means that CRSP’s stock grew similarly to CABA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CABACRSP
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 13 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CABA
Daily Signal:
Gain/Loss:
CRSP
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GPAGF20.62N/A
N/A
Gruma S.A.B. de CV
BYLB113.00N/A
N/A
Boyle Bancorp, Inc.
DTSOF6.21N/A
N/A
DTS Corp.
PPRUF341.02-8.98
-2.57%
Kering SA
STSBF0.10-0.02
-13.36%
South Star Battery Metals Corp.

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-5.45%
SYRE - CABA
44%
Loosely correlated
-4.53%
IPSC - CABA
44%
Loosely correlated
-0.55%
CLDX - CABA
44%
Loosely correlated
-4.03%
BEAM - CABA
43%
Loosely correlated
-5.05%
VYGR - CABA
42%
Loosely correlated
-3.42%
More